Tools and techniques – Page 16
-
ArticleDecoding stem cells for personalised regenerative medicine
Researchers developed a personalised stem cell therapy using a data-driven, single-cell technique based on swift subcellular proteomic imaging.
-
ArticleNew biomarkers found for diabetic kidney disease
Biomarkers found through urinary and exosome proteome profiling have potential for diagnosis and disease monitoring.
-
ArticleDrug Target Review Proteomics eBook 2023
Download now! Drug Target Review breaks down the potential of stem cells for personalised regenerative medicine, offering practical insights into their role in healthcare.
-
ArticleDrug Target Review Immuno-oncology eBook 2023
Download this eBook for FREE. Explore cutting-edge immuno-oncology insights through exclusive interviews and studies by leading experts in the field.
-
ArticleFramework for understanding cell organisation and variation
From a database of more than 200,000 high-resolution, three-dimensional images of human induced pluripotent stem cells, researchers have devised a model to quantify cell shape and internal organisation. Susanne Rafelski, Deputy Director of the Allen Institute for Cell Science, revealed details of their study to Drug Target Review.
-
ReportBeyond the lab: screening
Register to access the very latest research, insights and innovations including CRISPR activation screening, AI-aided screening and using nanofibrillar cellulose hydrogels.
-
ArticleAdvances in personalised medicine, leave data processing behind
The buzz around personalised medicine has long been felt in the halls of academic centres and pharmaceutical labs, and most people with an interest in health or medicine are aware of its potential. Here, Evan Floden shares what it will take to shore up these exciting possibilities.
-
ArticleCombining autotaxin and TGF-β inhibitors in cancer
Dr Catherine Pickering, CEO of iOnctura, the clinical stage biopharmaceutical company delivering pioneering cancer treatments to patients with unmet medical needs, is at the forefront of cancer drug discovery. Dr Pickering and her team identify targets that have crucial roles in multiple tumour survival pathways, collaborate with world-renowned scientists and ...
-
ArticleCAR-NK cells: promising for cancer therapy
The suitability of NK cells for cancer therapy has been challenged by some investor and business interests because of limited efficacy data, is this a valid belief at the present stage of development of the immune therapy field?
-
ArticleHow a dynein subunit maintains neuronal health
Understanding how a molecular transport system inside neurons works could be used for therapeutic approaches to neurodegenerative disease.
-
ArticleUnderstanding intracellular processes improves LYTACs therapy
New pathway involved in cellular protein degradation could develop LYTACs therapy and find new treatments for lysosome shortage disorders.
-
ArticleProtein offers promise for treatment of reproductive conditions
Scientists found that CXCR4 protein expression outside of the uterus is important for pregnancy maintenance.
-
ArticleEpisode 24 - Genetic engineering for allogeneic immunotherapy
Listen to this podcast where we dive into genetic engineering, its role and relationship with allogeneic immunotherapy.
-
ArticleAmino acid promotes tumour growth
Research into how the amino acid arginine drives metabolic reprogramming offers promise for liver cancer treatment.
-
ArticleDevelopments in trapped ion mobility spectrometry
Torsten Müller from Bruker Daltonics shares how trapped ion mobility spectrometry (TIMS) fundamentally improves immunopeptidomics research and addresses key challenges in this rapidly expanding field.
-
-
EventLiverpool Breakfast Briefing
Drug Target Review in association with ELRIG UK and BioIVT will host an exclusive, free-to-attend, breakfast briefing during the annual Drug Discovery event this October in Liverpool, UK. The highly anticipated breakfast briefing is open to all attendees of ELRIG’s Drug Discovery event, ELRIG UK and Drug Target Review members ...
-
ArticleEpisode 22 - The tumour microenvironment in immuno-oncology
Tune into this podcast to hear experts discussing the tumour microenvironment in immuno-oncology!
-
ArticleHuntington's disease and potential therapies
In this exclusive interview with Young Kwon, CEO of Alchemab, we discuss new platforms that are revolutionising how researchers identify naturally occurring antibodies in resilient individuals, opening up new possibilities for the development of disease-modifying therapies.
-
ArticleHPV-associated head and neck cancers identified
Human papillomavirus (HPV)-associated head and neck cancers, specifically head and neck squamous cell carcinoma (HNSCC), are on the rise worldwide. Yet, the factors contributing to these tumours and their varying responses to treatment remain poorly understood.